Header Logo

JERI KIM

TitleProfessor
InstitutionMD Anderson
DepartmentGenitourinary Medical Oncology
Address1155 Pressler St
Houston TX 77030-3721
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Gong J, Janes JL, Trustram Eve C, Stock S, Waller J, De Hoedt AM, Kim J, Ghate SR, Shui IM, Freedland SJ. Epidemiology, treatment patterns, and clinical outcomes in de novo oligometastatic hormone-sensitive prostate cancer. Cancer. 2024 Nov 15; 130(22):3815-3825. PMID: 38950063.
      Citations: 1     Fields:    Translation:Humans
    2. Wang A, Shen J, Rodriguez AA, Saunders EJ, Chen F, Janivara R, Darst BF, Sheng X, Xu Y, Chou AJ, Benlloch S, Dadaev T, Brook MN, Plym A, Sahimi A, Hoffman TJ, Takahashi A, Matsuda K, Momozawa Y, Fujita M, Laisk T, Figuer?do J, Muir K, Ito S, Liu X, Biobank Japan Project, Uchio Y, Kubo M, Kamatani Y, Lophatananon A, Wan P, Andrews C, Lori A, Choudhury PP, Schleutker J, Tammela TLJ, Sipeky C, Auvinen A, Giles GG, Southey MC, MacInnis RJ, Cybulski C, Wokolorczyk D, Lubinski J, Rentsch CT, Cho K, Mcmahon BH, Neal DE, Donovan JL, Hamdy FC, Martin RM, Nordestgaard BG, Nielsen SF, Weischer M, Bojesen SE, R?der A, Stroomberg HV, Batra J, Chambers S, Horvath L, Clements JA, Tilly W, Risbridger GP, Gronberg H, Aly M, Szulkin R, Eklund M, Nordstrom T, Pashayan N, Dunning AM, Ghoussaini M, Travis RC, Key TJ, Riboli E, Park JY, Sellers TA, Lin HY, Albanes D, Weinstein S, Cook MB, Mucci LA, Giovannucci E, Lindstrom S, Kraft P, Hunter DJ, Penney KL, Turman C, Tangen CM, Goodman PJ, Thompson IM, Hamilton RJ, Fleshner NE, Finelli A, Parent M?, Stanford JL, Ostrander EA, Koutros S, Beane Freeman LE, Stampfer M, Wolk A, H?kansson N, Andriole GL, Hoover RN, Machiela MJ, S?rensen KD, Borre M, Blot WJ, Zheng W, Yeboah ED, Mensah JE, Lu YJ, Zhang HW, Feng N, Mao X, Wu Y, Zhao SC, Sun Z, Thibodeau SN, McDonnell SK, Schaid DJ, West CML, Barnett G, Maier C, Schnoeller T, Luedeke M, Kibel AS, Drake BF, Cussenot O, Cancel-Tassin G, Menegaux F, Truong T, Koudou YA, John EM, Grindedal EM, Maehle L, Khaw KT, Ingles SA, Stern MC, Vega A, G?mez-Caama?o A, Fachal L, Rosenstein BS, Kerns SL, Ostrer H, Teixeira MR, Paulo P, Brand?o A, Watya S, Lubwama A, Bensen JT, Butler EN, Mohler JL, Taylor JA, Kogevinas M, Dierssen-Sotos T, Casta?o-Vinyals G, Cannon-Albright L, Teerlink CC, Huff CD, Pilie P, Yu Y, Bohlender RJ, Gu J, Strom SS, Multigner L, Blanchet P, Brureau L, Kaneva R, Slavov C, Mitev V, Leach RJ, Brenner H, Chen X, Holleczek B, Sch?ttker B, Klein EA, Hsing AW, Kittles RA, Murphy AB, Logothetis CJ, Kim J, Neuhausen SL, Steele L, Ding YC, Isaacs WB, Nemesure B, Hennis AJM, Carpten J, Pandha H, Michael A, De Ruyck K, De Meerleer G, Ost P, Xu J, Razack A, Lim J, Teo SH, Newcomb LF, Lin DW, Fowke JH, Neslund-Dudas CM, Rybicki BA, Gamulin M, Lessel D, Kulis T, Usmani N, Abraham A, Singhal S, Parliament M, Claessens F, Joniau S, Van den Broeck T, Gago-Dominguez M, Castelao JE, Martinez ME, Larkin S, Townsend PA, Aukim-Hastie C, Bush WS, Aldrich MC, Crawford DC, Srivastava S, Cullen J, Petrovics G, Casey G, Wang Y, Tettey Y, Lachance J, Tang W, Biritwum RB, Adjei AA, Tay E, Truelove A, Niwa S, Yamoah K, Govindasami K, Chokkalingam AP, Keaton JM, Hellwege JN, Clark PE, Jalloh M, Gueye SM, Niang L, Ogunbiyi O, Shittu O, Amodu O, Adebiyi AO, Aisuodionoe-Shadrach OI, Ajibola HO, Jamda MA, Oluwole OP, Nwegbu M, Adusei B, Mante S, Darkwa-Abrahams A, Diop H, Gundell SM, Roobol MJ, Jenster G, van Schaik RHN, Hu JJ, Sanderson M, Kachuri L, Varma R, McKean-Cowdin R, Torres M, Preuss MH, Loos RJF, Zawistowski M, Z?llner S, Lu Z, Van Den Eeden SK, Easton DF, Ambs S, Edwards TL, M?gi R, Rebbeck TR, Fritsche L, Chanock SJ, Berndt SI, Wiklund F, Nakagawa H, Witte JS, Gaziano JM, Justice AC, Mancuso N, Terao C, Eeles RA, Kote-Jarai Z, Madduri RK, Conti DV, Haiman CA. Characterizing prostate cancer risk through multi-ancestry genome-wide discovery of 187 novel risk variants. Nat Genet. 2023 Dec; 55(12):2065-2074. PMID: 37945903; PMCID: PMC10841479.
      Citations: 2     Fields:    Translation:Humans
    3. Antonarakis ES, Park SH, Goh JC, Shin SJ, Lee JL, Mehra N, McDermott R, Sala-Gonzalez N, Fong PC, Greil R, Retz M, Sade JP, Yanez P, Huang YH, Begbie SD, Gafanov RA, De Santis M, Rosenbaum E, Kolinsky MP, Rey F, Chiu KY, Roubaud G, Kramer G, Sumitomo M, Massari F, Suzuki H, Qiu P, Zhang J, Kim J, Poehlein CH, Yu EY. Pembrolizumab Plus Olaparib for Patients With Previously Treated and Biomarker-Unselected Metastatic Castration-Resistant Prostate Cancer: The Randomized, Open-Label, Phase III KEYLYNK-010 Trial. J Clin Oncol. 2023 08 01; 41(22):3839-3850. PMID: 37290035; PMCID: PMC10419579.
      Citations: 12     Fields:    Translation:Humans
    4. Swami U, Aggarwal H, Zhou M, Jiang S, Kim J, Li W, Lalibert? F, Emond B, Agarwal N. Treatment Patterns, Clinical Outcomes, Health Care Resource Utilization and Costs in Older Patients With Metastatic Castration-Resistant Prostate Cancer in the United States: An Analysis of SEER-Medicare Data. Clin Genitourin Cancer. 2023 10; 21(5):517-529. PMID: 37248148.
      Citations: 1     Fields:    Translation:Humans
    5. Gregg JR, Kim J, Logothetis C, Hanash S, Zhang X, Manyam G, Muir K, UKGPCS Collaborative Group, Giles GG, Stanford JL, Berndt SI, Kogevinas M, Brenner H, Eeles RA, PRACTICAL Consortium, Wei P, Daniel CR. Coffee Intake, Caffeine Metabolism Genotype, and Survival Among Men with Prostate Cancer. Eur Urol Oncol. 2023 Jun; 6(3):282-288. PMID: 35995710; PMCID: PMC9939555.
      Citations:    
    6. Leith A, Ribbands A, Kim J, Clayton E, Gillespie-Akar L, Yang L, Ghate SR. Impact of next-generation hormonal agents on treatment patterns among patients with metastatic hormone-sensitive prostate cancer: a real-world study from the United States, five European countries and Japan. BMC Urol. 2022 Mar 11; 22(1):33. PMID: 35277153; PMCID: PMC8915525.
      Citations:    Fields:    Translation:Humans
    7. Jiang Y, Meyers TJ, Emeka AA, Cooley LF, Cooper PR, Lancki N, Helenowski I, Kachuri L, Lin DW, Stanford JL, Newcomb LF, Kolb S, Finelli A, Fleshner NE, Komisarenko M, Eastham JA, Ehdaie B, Benfante N, Logothetis CJ, Gregg JR, Perez CA, Garza S, Kim J, Marks LS, Delfin M, Barsa D, Vesprini D, Klotz LH, Loblaw A, Mamedov A, Goldenberg SL, Higano CS, Spillane M, Wu E, Carter HB, Pavlovich CP, Mamawala M, Landis T, Carroll PR, Chan JM, Cooperberg MR, Cowan JE, Morgan TM, Siddiqui J, Martin R, Klein EA, Brittain K, Gotwald P, Barocas DA, Dallmer JR, Gordetsky JB, Steele P, Kundu SD, Stockdale J, Roobol MJ, Venderbos LDF, Sanda MG, Arnold R, Patil D, Evans CP, Dall'Era MA, Vij A, Costello AJ, Chow K, Corcoran NM, Rais-Bahrami S, Phares C, Scherr DS, Flynn T, Karnes RJ, Koch M, Dhondt CR, Nelson JB, McBride D, Cookson MS, Stratton KL, Farriester S, Hemken E, Stadler WM, Pera T, Banionyte D, Bianco FJ, Lopez IH, Loeb S, Taneja SS, Byrne N, Amling CL, Martinez A, Boileau L, Gaylis FD, Petkewicz J, Kirwen N, Helfand BT, Xu J, Scholtens DM, Catalona WJ, Witte JS. Genetic Factors Associated with Prostate Cancer Conversion from Active Surveillance to Treatment. HGG Adv. 2022 Jan 13; 3(1). PMID: 34993496; PMCID: PMC8725988.
      Citations: 3     
    8. Conti DV, Darst BF, Moss LC, Saunders EJ, Sheng X, Chou A, Schumacher FR, Olama AAA, Benlloch S, Dadaev T, Brook MN, Sahimi A, Hoffmann TJ, Takahashi A, Matsuda K, Momozawa Y, Fujita M, Muir K, Lophatananon A, Wan P, Le Marchand L, Wilkens LR, Stevens VL, Gapstur SM, Carter BD, Schleutker J, Tammela TLJ, Sipeky C, Auvinen A, Giles GG, Southey MC, MacInnis RJ, Cybulski C, Wokolorczyk D, Lubinski J, Neal DE, Donovan JL, Hamdy FC, Martin RM, Nielsen SF, Weischer M, Bojesen SE, Iversen P, Batra J, Chambers S, Moya L, Horvath L, Clements JA, Tilley W, Risbridger GP, Gronberg H, Aly M, Szulkin R, Eklund M, Pashayan N, Dunning AM, Ghoussaini M, Travis RC, Key TJ, Riboli E, Park JY, Sellers TA, Lin HY, Albanes D, Weinstein SJ, Mucci LA, Giovannucci E, Lindstrom S, Kraft P, Hunter DJ, Penney KL, Turman C, Tangen CM, Goodman PJ, Thompson IM, Hamilton RJ, Fleshner NE, Finelli A, Stanford JL, Ostrander EA, Geybels MS, Koutros S, Freeman LEB, Stampfer M, Wolk A, Andriole GL, Hoover RN, Machiela MJ, Borre M, Blot WJ, Zheng W, Yeboah ED, Mensah JE, Lu YJ, Zhang HW, Feng N, Mao X, Wu Y, Zhao SC, Sun Z, Thibodeau SN, McDonnell SK, Schaid DJ, West CML, Burnet N, Barnett G, Maier C, Schnoeller T, Luedeke M, Kibel AS, Drake BF, Cussenot O, Menegaux F, Koudou YA, John EM, Grindedal EM, Maehle L, Khaw KT, Ingles SA, Stern MC, Fachal L, Rosenstein BS, Kerns SL, Ostrer H, Teixeira MR, Paulo P, Watya S, Lubwama A, Bensen JT, Fontham ETH, Mohler J, Taylor JA, Kogevinas M, Cannon-Albright L, Teerlink CC, Huff CD, Strom SS, Multigner L, Kaneva R, Slavov C, Mitev V, Leach RJ, Weaver B, Brenner H, Cuk K, Saum KU, Klein EA, Hsing AW, Kittles RA, Murphy AB, Logothetis CJ, Kim J, Neuhausen SL, Steele L, Ding YC, Isaacs WB, Nemesure B, Hennis AJM, Carpten J, Pandha H, Michael A, De Ruyck K, De Meerleer G, Ost P, Xu J, Razack A, Lim J, Teo SH, Newcomb LF, Lin DW, Fowke JH, Neslund-Dudas C, Rybicki BA, Gamulin M, Lessel D, Kulis T, Usmani N, Singhal S, Parliament M, Claessens F, Joniau S, Van den Broeck T, Martinez ME, Larkin S, Townsend PA, Aukim-Hastie C, Bush WS, Aldrich MC, Crawford DC, Srivastava S, Cullen JC, Petrovics G, Casey G, Roobol MJ, Jenster G, van Schaik RHN, Hu JJ, Sanderson M, Varma R, McKean-Cowdin R, Torres M, Mancuso N, Berndt SI, Van Den Eeden SK, Easton DF, Chanock SJ, Cook MB, Wiklund F, Nakagawa H, Witte JS, Eeles RA, Kote-Jarai Z, Haiman CA, Nordestgaard BG, R?der MA, Nordstr?m T, Parent M?, H?kansson N, S?rensen KD, Cancel-Tassin G, Truong T, Vega A, G?mez-Caama?o A, Brand?o A, Llorca J, Casta?o-Vinyals G, Blanchet P, Brureau L, Holleczek B, Gago-Dominguez M, Castelao JE. Publisher Correction: Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction. Nat Genet. 2021 Mar; 53(3):413. PMID: 33473200.
      Citations: 1     Fields:    
    9. Gregg JR, Zhang X, Chapin BF, Ward JF, Kim J, Davis JW, Daniel CR. Adherence to the Mediterranean diet and grade group progression in localized prostate cancer: An active surveillance cohort. Cancer. 2021 03 01; 127(5):720-728. PMID: 33411364; PMCID: PMC9810094.
      Citations: 3     Fields:    Translation:Humans
    10. Conti DV, Darst BF, Moss LC, Saunders EJ, Sheng X, Chou A, Schumacher FR, Olama AAA, Benlloch S, Dadaev T, Brook MN, Sahimi A, Hoffmann TJ, Takahashi A, Matsuda K, Momozawa Y, Fujita M, Muir K, Lophatananon A, Wan P, Le Marchand L, Wilkens LR, Stevens VL, Gapstur SM, Carter BD, Schleutker J, Tammela TLJ, Sipeky C, Auvinen A, Giles GG, Southey MC, MacInnis RJ, Cybulski C, Wokolorczyk D, Lubinski J, Neal DE, Donovan JL, Hamdy FC, Martin RM, Nielsen SF, Weischer M, Bojesen SE, Iversen P, Batra J, Chambers S, Moya L, Horvath L, Clements JA, Tilley W, Risbridger GP, Gronberg H, Aly M, Szulkin R, Eklund M, Pashayan N, Dunning AM, Ghoussaini M, Travis RC, Key TJ, Riboli E, Park JY, Sellers TA, Lin HY, Albanes D, Weinstein SJ, Mucci LA, Giovannucci E, Lindstrom S, Kraft P, Hunter DJ, Penney KL, Turman C, Tangen CM, Goodman PJ, Thompson IM, Hamilton RJ, Fleshner NE, Finelli A, Stanford JL, Ostrander EA, Geybels MS, Koutros S, Freeman LEB, Stampfer M, Wolk A, Andriole GL, Hoover RN, Machiela MJ, Borre M, Blot WJ, Zheng W, Yeboah ED, Mensah JE, Lu YJ, Zhang HW, Feng N, Mao X, Wu Y, Zhao SC, Sun Z, Thibodeau SN, McDonnell SK, Schaid DJ, West CML, Burnet N, Barnett G, Maier C, Schnoeller T, Luedeke M, Kibel AS, Drake BF, Cussenot O, Menegaux F, Koudou YA, John EM, Grindedal EM, Maehle L, Khaw KT, Ingles SA, Stern MC, Fachal L, Rosenstein BS, Kerns SL, Ostrer H, Teixeira MR, Paulo P, Watya S, Lubwama A, Bensen JT, Fontham ETH, Mohler J, Taylor JA, Kogevinas M, Cannon-Albright L, Teerlink CC, Huff CD, Strom SS, Multigner L, Kaneva R, Slavov C, Mitev V, Leach RJ, Weaver B, Brenner H, Cuk K, Saum KU, Klein EA, Hsing AW, Kittles RA, Murphy AB, Logothetis CJ, Kim J, Neuhausen SL, Steele L, Ding YC, Isaacs WB, Nemesure B, Hennis AJM, Carpten J, Pandha H, Michael A, De Ruyck K, De Meerleer G, Ost P, Xu J, Razack A, Lim J, Teo SH, Newcomb LF, Lin DW, Fowke JH, Neslund-Dudas C, Rybicki BA, Gamulin M, Lessel D, Kulis T, Usmani N, Singhal S, Parliament M, Claessens F, Joniau S, Van den Broeck T, Martinez ME, Larkin S, Townsend PA, Aukim-Hastie C, Bush WS, Aldrich MC, Crawford DC, Srivastava S, Cullen JC, Petrovics G, Casey G, Roobol MJ, Jenster G, van Schaik RHN, Hu JJ, Sanderson M, Varma R, McKean-Cowdin R, Torres M, Mancuso N, Berndt SI, Van Den Eeden SK, Easton DF, Chanock SJ, Cook MB, Wiklund F, Nakagawa H, Witte JS, Eeles RA, Kote-Jarai Z, Haiman CA, Nordestgaard BG, R?der MA, Nordstr?m T, Parent M?, H?kansson N, S?rensen KD, Cancel-Tassin G, Truong T, Vega A, G?mez-Caama?o A, Brand?o A, Llorca J, Casta?o-Vinyals G, Blanchet P, Brureau L, Holleczek B, Gago-Dominguez M, Castelao JE. Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction. Nat Genet. 2021 01; 53(1):65-75. PMID: 33398198; PMCID: PMC8148035.
      Citations: 55     Fields:    Translation:Humans
    11. Shore N, Oliver L, Shui I, Gayle A, Wong OY, Kim J, Payne S, Amin S, Ghate S. Systematic Literature Review of the Epidemiology of Advanced Prostate Cancer and Associated Homologous Recombination Repair Gene Alterations. J Urol. 2021 04; 205(4):977-986. PMID: 33332152.
      Citations: 2     Fields:    Translation:HumansCells
    12. Vykoukal J, Fahrmann JF, Gregg JR, Tang Z, Basourakos S, Irajizad E, Park S, Yang G, Creighton CJ, Fleury A, Mayo J, Paulucci-Holthauzen A, Dennison JB, Murage E, Peterson CB, Davis JW, Kim J, Hanash S, Thompson TC. Caveolin-1-mediated sphingolipid oncometabolism underlies a metabolic vulnerability of prostate cancer. Nat Commun. 2020 08 27; 11(1):4279. PMID: 32855410; PMCID: PMC7453025.
      Citations: 19     Fields:    Translation:HumansAnimalsCells
    13. Deng Y, Xie K, Logothetis CJ, Thompson TC, Kim J, Huang M, Chang DW, Gu J, Wu X, Ye Y. Genetic variants in epithelial-mesenchymal transition genes as predictors of clinical outcomes in localized prostate cancer. Carcinogenesis. 2020 08 12; 41(8):1057-1064. PMID: 32215555; PMCID: PMC7422619.
      Citations:    Fields:    Translation:Humans
    14. Gregg JR, Surasi DS, Childs A, Moll N, Ward JF, Kim J, Daniel CR, Logothetis C, Bathala T, Davis JW. The Association of Periprostatic Fat and Grade Group Progression in Men with Localized Prostate Cancer on Active Surveillance. J Urol. 2021 Jan; 205(1):122-128. PMID: 32718204; PMCID: PMC9810079.
      Citations: 2     Fields:    Translation:Humans
    15. Spetsieris N, Boukovala M, Weldon JA, Tsikkinis A, Hoang A, Aparicio A, Tu SM, Araujo JC, Zurita AJ, Corn PG, Pagliaro L, Kim J, Wang J, Subudhi SK, Tannir NM, Logothetis CJ, Troncoso P, Wang X, Wen S, Efstathiou E. A Phase 2 Trial of Abiraterone Followed by Randomization to Addition of Dasatinib or Sunitinib in Men With Metastatic Castration-Resistant Prostate Cancer. Clin Genitourin Cancer. 2021 02; 19(1):22-31.e5. PMID: 32675015; PMCID: PMC10014037.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    16. Boukovala M, Spetsieris N, Weldon JA, Tsikkinis A, Hoang A, Aparicio A, Tu SM, Araujo JC, Zurita AJ, Corn PG, Pagliaro L, Kim J, Wang J, Subudhi SK, Tannir NM, Logothetis CJ, Troncoso P, Wen S, Efstathiou E. A candidate androgen signalling signature predictive of response to abiraterone acetate in men with metastatic castration-resistant prostate cancer. Eur J Cancer. 2020 03; 127:67-75. PMID: 31986451; PMCID: PMC7350510.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    17. Gregg JR, Davis JW, Reichard C, Wang X, Achim M, Chapin BF, Pisters L, Pettaway C, Ward JF, Choi S, Nguyen QN, Kuban D, Babaian R, Troncoso P, Madsen LT, Logothetis C, Kim J. Determining Clinically Based Factors Associated With Reclassification in the Pre-MRI Era using a Large Prospective Active Surveillance Cohort. Urology. 2020 04; 138:91-97. PMID: 31899230; PMCID: PMC7141963.
      Citations: 2     Fields:    Translation:Humans
    18. Antonarakis ES, Goh J, Ojamaa K, Hoimes CJ, Vaishampayan U, Berger R, Sezer A, Alanko T, de Wit R, Li C, Omlin A, Procopio G, Fukasawa S, Tabata KI, Park SH, Drake CG, Wu H, Qiu P, Kim J, Poehlein C, de Bono JS, Piulats JM, Gross-Goupil M, Feyerabend S. Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study. J Clin Oncol. 2020 02 10; 38(5):395-405. PMID: 31774688; PMCID: PMC7186583.
      Citations: 154     Fields:    Translation:HumansCTClinical Trials
    19. Jiang X, Finucane HK, Schumacher FR, Schmit SL, Tyrer JP, Han Y, Michailidou K, Lesseur C, Kuchenbaecker KB, Dennis J, Conti DV, Casey G, Gaudet MM, Huyghe JR, Albanes D, Aldrich MC, Andrew AS, Andrulis IL, Anton-Culver H, Antoniou AC, Antonenkova NN, Arnold SM, Aronson KJ, Arun BK, Bandera EV, Barkardottir RB, Barnes DR, Batra J, Beckmann MW, Benlloch S, Berchuck A, Berndt SI, Bien SA, Blomqvist C, Boccia S, Bogdanova NV, Bojesen SE, Bolla MK, Brauch H, Brenner H, Brenton JD, Brook MN, Buchanan DD, Burwinkel B, Butzow R, Cadoni G, Caligo MA, Campbell I, Campbell PT, Cannon-Albright L, Campa D, Caporaso N, Chan AT, Chang-Claude J, Chanock SJ, Chen C, Christiani DC, Claes KBM, Claessens F, Clements J, Correa MC, Couch FJ, Cox A, Cunningham JM, Cybulski C, Czene K, Daly MB, deFazio A, Devilee P, Diez O, Donovan JL, Duell EJ, Dunning AM, Dwek M, Eccles DM, Edlund CK, Edwards DRV, Evans DG, Fasching PA, Ferris RL, Liloglou T, Figueiredo JC, Fletcher O, Fostira F, Franceschi S, Friedman E, Gallinger SJ, Ganz PA, Garber J, Gayther SA, Giles GG, Godwin AK, Goldgar DE, Goode EL, Goodman MT, Goodman G, Greene MH, Gronberg H, Gronwald J, Hall P, Hamann U, Hamdy FC, Hamilton RJ, Haugen A, Herrero R, Hoffmeister M, Hong YC, Hopper JL, Houlston R, Hulick PJ, Hunter DJ, Huntsman DG, Idos G, Imyanitov EN, Ingles SA, Isaacs C, Jakubowska A, James P, Jenkins MA, Johansson M, John EM, Joshi AD, Kaneva R, Karlan BY, Kelemen LE, Khaw KT, Khusnutdinova E, Kibel AS, Kiemeney LA, Kim J, Kjaer SK, Knight JA, Kote-Jarai Z, Koutros S, Kristensen VN, Kupryjanczyk J, Lacko M, Lam S, Lambrechts D, Landi MT, Lazarus P, Le ND, Lee E, Lejbkowicz F, Lenz HJ, Leslie G, Lester J, Levine DA, Li L, Li CI, Lindblom A, Lindor NM, Liu G, Loupakis F, Lubinski J, Maehle L, Maier C, Mannermaa A, Marchand LL, May T, McGuffog L, Middha P, Miller A, Milne RL, MacInnis RJ, Modugno F, Montagna M, Moreno V, Moysich KB, Mucci L, Muir K, Mulligan AM, Nathanson KL, Neal DE, Ness AR, Neuhausen SL, Nevanlinna H, Newcomb PA, Newcomb LF, Nielsen FC, Nikitina-Zake L, Nussbaum RL, Offit K, Olama AAA, Olopade OI, Olshan AF, Pandha H, Park JY, Pashayan N, Parsons MT, Pejovic T, Penney KL, Peters WHM, Phelan CM, Phipps AI, Plaseska-Karanfilska D, Pring M, Prokofyeva D, Radice P, Stefansson K, Ramus SJ, Raskin L, Rennert G, Rennert HS, van Rensburg EJ, Riggan MJ, Risch HA, Risch A, Roobol MJ, Rosenstein BS, Rossing MA, De Ruyck K, Saloustros E, Sandler DP, Sawyer EJ, Schabath MB, Schleutker J, Schmidt MK, Setiawan VW, Shen H, Siegel EM, Sieh W, Singer CF, Slattery ML, Sorensen KD, Southey MC, Spurdle AB, Stanford JL, Stevens VL, Stintzing S, Stone J, Sutphen R, Swerdlow AJ, Tangen CM, Tardon A, Taylor JA, Teare MD, Terry MB, Terry KL, Thibodeau SN, Thomassen M, Toland AE, Torres D, Townsend PA, Travis RC, Tung N, Tworoger SS, Ulrich CM, Usmani N, Vachon CM, Van Nieuwenhuysen E, Wang Q, Webb PM, Weinberg CR, Weinstein S, Weissler MC, Weitzel JN, West CML, White E, Whittemore AS, Wichmann HE, Wiklund F, Winqvist R, Woll P, Woods M, Wu AH, Wu X, Yannoukakos D, Zheng W, Zienolddiny S, Ziogas A, Zorn KK, Lane JM, Saxena R, Thomas D, Hung RJ, Diergaarde B, McKay J, Peters U, Hsu L, Eeles RA, Chenevix-Trench G, Brennan PJ, Haiman CA, Easton DF, Gruber SB, Pharoah PDP, Price AL, Pasaniuc B, Amos CI, Kraft P, Benitez J, Bickeb?ller H, Brunet J, Brunnstr?m H, Cald?s T, Cancel-Tassin G, Carvalho AL, Coll?e JM, Gago-Dominguez M, D?rk T, Ellberg C, Fortner RT, Garc?a-S?enz JA, Goldberg MS, Grankvist K, Gu?nel P, H?kansson N, Hampe J, Heitz F, Hillemanns P, H?gdall E, Johansson M, K?hl T, Kogevinas M, Lessel D, Margolin S, Meindl A, Nordestgaard BG, Olah E, Olsson H, Osorio A, Sundfeldt K, Tajara EH, Teixeira MR, Bj?rge L, Tischkowitz M, Vega A, Aguado-Barrera ME, Wolk A, Garc?a-Closas M, Simard J, Lindstr?m S. Publisher Correction: Shared heritability and functional enrichment across six solid cancers. Nat Commun. 2019 Sep 23; 10(1):4386. PMID: 31548585; PMCID: PMC6757065.
      Citations:    Fields:    
    20. Lowenstein LM, Williams MD, Troncoso P, Thompson TC, Kim J, Basourakos SP, Gregg JR. Active surveillance for prostate and thyroid cancers: evolution in clinical paradigms and lessons learned. Nat Rev Clin Oncol. 2019 03; 16(3):168-184. PMID: 30413793; PMCID: PMC6501050.
      Citations: 13     Fields:    Translation:HumansPHPublic Health
    21. Schumacher FR, Olama AAA, Berndt SI, Benlloch S, Ahmed M, Saunders EJ, Dadaev T, Leongamornlert D, Anokian E, Cieza-Borrella C, Goh C, Brook MN, Sheng X, Dennis J, Tyrer J, Muir K, Lophatananon A, Stevens VL, Gapstur SM, Carter BD, Tangen CM, Goodman PJ, Thompson IM, Batra J, Chambers S, Moya L, Clements J, Horvath L, Tilley W, Risbridger GP, Gronberg H, Aly M, Pharoah P, Pashayan N, Schleutker J, Tammela TLJ, Sipeky C, Auvinen A, Albanes D, Weinstein S, Wolk A, West CML, Dunning AM, Burnet N, Mucci LA, Giovannucci E, Andriole GL, Koutros S, Beane Freeman LE, Sorensen KD, Orntoft TF, Borre M, Maehle L, Grindedal EM, Neal DE, Donovan JL, Hamdy FC, Martin RM, Travis RC, Key TJ, Hamilton RJ, Fleshner NE, Finelli A, Ingles SA, Stern MC, Rosenstein BS, Kerns SL, Ostrer H, Lu YJ, Zhang HW, Feng N, Mao X, Guo X, Wang G, Sun Z, Giles GG, Southey MC, MacInnis RJ, FitzGerald LM, Kibel AS, Drake BF, Szulkin R, Eklund M, Kogevinas M, Penney KL, Stampfer M, Park JY, Sellers TA, Lin HY, Stanford JL, Cybulski C, Wokolorczyk D, Lubinski J, Ostrander EA, Geybels MS, Nielsen SF, Weischer M, Bisbjerg R, Iversen P, Brenner H, Cuk K, Maier C, Luedeke M, Schnoeller T, Kim J, Logothetis CJ, John EM, Teixeira MR, Paulo P, Cardoso M, Neuhausen SL, Steele L, Ding YC, De Ruyck K, De Meerleer G, Ost P, Razack A, Lim J, Teo SH, Lin DW, Newcomb LF, Lessel D, Gamulin M, Kulis T, Kaneva R, Usmani N, Singhal S, Slavov C, Mitev V, Parliament M, Claessens F, Joniau S, Van den Broeck T, Larkin S, Townsend PA, Aukim-Hastie C, Martinez ME, Roobol MJ, Jenster G, van Schaik RHN, Menegaux F, Koudou YA, Xu J, Khaw KT, Cannon-Albright L, Pandha H, Michael A, Thibodeau SN, McDonnell SK, Schaid DJ, Lindstrom S, Turman C, Ma J, Hunter DJ, Riboli E, Siddiq A, Canzian F, Kolonel LN, Le Marchand L, Hoover RN, Machiela MJ, Cui Z, Kraft P, Amos CI, Conti DV, Easton DF, Wiklund F, Chanock SJ, Henderson BE, Kote-Jarai Z, Haiman CA, Eeles RA, Profile Study, Australian Prostate Cancer BioResource (APCB), IMPACT Study, Canary PASS Investigators, Breast and Prostate Cancer Cohort Consortium (BPC3), PRACTICAL (Prostate Cancer Association Group to Investigate Cancer-Associated Alterations in the Gen, Cancer of the Prostate in Sweden (CAPS), Prostate Cancer Genome-wide Association Study of Uncommon Susceptibility Loci (PEGASUS), Genetic Associations and Mechanisms in Oncology (GAME-ON)/Elucidating Loci Involved in Prostate Canc, Fachal L, Nordstr?m T, H?kansson N, Cussenot O, Cancel-Tassin G, Vega A, G?mez-Caama?o A, Llorca J, Casta?o-Vinyals G, Nordestgaard BG, R?der MA, Holleczek B, Gago-Dominguez M, Castelao JE, Truong T. Author Correction: Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci. Nat Genet. 2019 02; 51(2):363. PMID: 30622367.
      Citations: 2     Fields:    
    22. Gregg JR, Lopez DS, Reichard C, Zheng J, Wu W, Ye Y, Chapin B, Kim J, Daniel CR, Davis J. Coffee, Caffeine Metabolism Genotype and Disease Progression in Patients with Localized Prostate Cancer Managed with Active Surveillance. J Urol. 2019 02; 201(2):308-314. PMID: 30179617; PMCID: PMC9798525.
      Citations: 2     Fields:    Translation:Humans
    23. Gregg JR, Zheng J, Lopez DS, Reichard C, Browman G, Chapin B, Kim J, Davis J, Daniel CR. Diet quality and Gleason grade progression among localised prostate cancer patients on active surveillance. Br J Cancer. 2019 02; 120(4):466-471. PMID: 30679782; PMCID: PMC6462004.
      Citations: 2     Fields:    Translation:Humans
    24. Jiang X, Finucane HK, Schumacher FR, Schmit SL, Tyrer JP, Han Y, Michailidou K, Lesseur C, Kuchenbaecker KB, Dennis J, Conti DV, Casey G, Gaudet MM, Huyghe JR, Albanes D, Aldrich MC, Andrew AS, Andrulis IL, Anton-Culver H, Antoniou AC, Antonenkova NN, Arnold SM, Aronson KJ, Arun BK, Bandera EV, Barkardottir RB, Barnes DR, Batra J, Beckmann MW, Benlloch S, Berchuck A, Berndt SI, Bien SA, Blomqvist C, Boccia S, Bogdanova NV, Bojesen SE, Bolla MK, Brauch H, Brenner H, Brenton JD, Brook MN, Buchanan DD, Burwinkel B, Butzow R, Cadoni G, Caligo MA, Campbell I, Campbell PT, Cannon-Albright L, Campa D, Caporaso N, Chan AT, Chang-Claude J, Chanock SJ, Chen C, Christiani DC, Claes KBM, Claessens F, Clements J, Correa MC, Couch FJ, Cox A, Cunningham JM, Cybulski C, Czene K, Daly MB, deFazio A, Devilee P, Diez O, Donovan JL, Duell EJ, Dunning AM, Dwek M, Eccles DM, Edlund CK, Edwards DRV, Evans DG, Fasching PA, Ferris RL, Liloglou T, Figueiredo JC, Fletcher O, Fostira F, Franceschi S, Friedman E, Gallinger SJ, Ganz PA, Garber J, Gayther SA, Giles GG, Godwin AK, Goldgar DE, Goode EL, Goodman MT, Goodman G, Greene MH, Gronberg H, Gronwald J, Hall P, Hamann U, Hamdy FC, Hamilton RJ, Haugen A, Herrero R, Hoffmeister M, Hong YC, Hopper JL, Houlston R, Hulick PJ, Hunter DJ, Huntsman DG, Idos G, Imyanitov EN, Ingles SA, Isaacs C, Jakubowska A, James P, Jenkins MA, Johansson M, John EM, Joshi AD, Kaneva R, Karlan BY, Kelemen LE, Khaw KT, Khusnutdinova E, Kibel AS, Kiemeney LA, Kim J, Kjaer SK, Knight JA, Kote-Jarai Z, Koutros S, Kristensen VN, Kupryjanczyk J, Lacko M, Lam S, Lambrechts D, Landi MT, Lazarus P, Le ND, Lee E, Lejbkowicz F, Lenz HJ, Leslie G, Lester J, Levine DA, Li L, Li CI, Lindblom A, Lindor NM, Liu G, Loupakis F, Lubinski J, Maehle L, Maier C, Mannermaa A, Marchand LL, May T, McGuffog L, Middha P, Miller A, Milne RL, MacInnis RJ, Modugno F, Montagna M, Moreno V, Moysich KB, Mucci L, Muir K, Mulligan AM, Nathanson KL, Neal DE, Ness AR, Neuhausen SL, Nevanlinna H, Newcomb PA, Newcomb LF, Nielsen FC, Nikitina-Zake L, Nussbaum RL, Offit K, Olama AAA, Olopade OI, Olshan AF, Pandha H, Park JY, Pashayan N, Parsons MT, Pejovic T, Penney KL, Peters WHM, Phelan CM, Phipps AI, Plaseska-Karanfilska D, Pring M, Prokofyeva D, Radice P, Stefansson K, Ramus SJ, Raskin L, Rennert G, Rennert HS, van Rensburg EJ, Riggan MJ, Risch HA, Risch A, Roobol MJ, Rosenstein BS, Rossing MA, De Ruyck K, Saloustros E, Sandler DP, Sawyer EJ, Schabath MB, Schleutker J, Schmidt MK, Setiawan VW, Shen H, Siegel EM, Sieh W, Singer CF, Slattery ML, Sorensen KD, Southey MC, Spurdle AB, Stanford JL, Stevens VL, Stintzing S, Stone J, Sutphen R, Swerdlow AJ, Tangen CM, Tardon A, Taylor JA, Teare MD, Terry MB, Terry KL, Thibodeau SN, Thomassen M, Toland AE, Torres D, Townsend PA, Travis RC, Tung N, Tworoger SS, Ulrich CM, Usmani N, Vachon CM, Van Nieuwenhuysen E, Wang Q, Webb PM, Weinberg CR, Weinstein S, Weissler MC, Weitzel JN, West CML, White E, Whittemore AS, Wichmann HE, Wiklund F, Winqvist R, Woll P, Woods M, Wu AH, Wu X, Yannoukakos D, Zheng W, Zienolddiny S, Ziogas A, Zorn KK, Lane JM, Saxena R, Thomas D, Hung RJ, Diergaarde B, McKay J, Peters U, Hsu L, Eeles RA, Chenevix-Trench G, Brennan PJ, Haiman CA, Easton DF, Gruber SB, Pharoah PDP, Price AL, Pasaniuc B, Amos CI, Kraft P, Benitez J, Bickeb?ller H, Brunet J, Brunnstr?m H, Cald?s T, Cancel-Tassin G, Carvalho AL, Coll?e JM, Gago-Dominguez M, D?rk T, Ellberg C, Fortner RT, Garc?a-S?enz JA, Goldberg MS, Grankvist K, Gu?nel P, H?kansson N, Hampe J, Heitz F, Hillemanns P, H?gdall E, Johansson M, K?hl T, Kogevinas M, Lessel D, Margolin S, Meindl A, Nordestgaard BG, Olah E, Olsson H, Osorio A, Sundfeldt K, Tajara EH, Teixeira MR, Bj?rge L, Tischkowitz M, Vega A, Aguado-Barrera ME, Wolk A, Garc?a-Closas M, Simard J, Lindstr?m S. Shared heritability and functional enrichment across six solid cancers. Nat Commun. 2019 01 25; 10(1):431. PMID: 30683880; PMCID: PMC6347624.
      Citations: 31     Fields:    Translation:Humans
    25. Wang Q, Gregg JR, Gu J, Ye Y, Chang DW, Davis JW, Thompson TC, Kim J, Logothetis CJ, Wu X. Genetic associations of T cell cancer immune response with tumor aggressiveness in localized prostate cancer patients and disease reclassification in an active surveillance cohort. Oncoimmunology. 2019; 8(1):e1483303. PMID: 30546938; PMCID: PMC6287782.
      Citations: 3     Fields:    
    26. Adams CD, Richmond R, Ferreira DLS, Spiller W, Tan V, Zheng J, Donovan J, Hamdy F, Neal D, Lane JA, Smith GD, Relton C, Eeles RA, Haiman CA, Kote-Jarai Z, Schumacher FR, Olama AAA, Benlloch S, Muir K, Berndt SI, Conti DV, Wiklund F, Chanock SJ, Gapstur S, Stevens VL, Tangen CM, Batra J, Clements JA, Gronberg H, Pashayan N, Schleutker J, Albanes D, Wolk A, West CML, Mucci LA, Koutros S, Sorensen KD, Maehle L, Travis RC, Hamilton RJ, Ingles SA, Rosenstein BS, Lu YJ, Giles GG, Kibel AS, Kogevinas M, Penney KL, Park JY, Stanford JL, Cybulski C, Brenner H, Maier C, Kim J, John EM, Teixeira MR, Neuhausen SL, De Ruyck K, Razack A, Newcomb LF, Lessel D, Kaneva RP, Usmani N, Claessens F, Townsend PA, Roobol MJ, Menegaux F, Khaw KT, Cannon-Albright LA, Pandha H, Thibodeau SN, Martin RM, PRACTICAL consortium, W?rtz P, Cancel-Tassin G, Vega A, Nordestgaard BG, Dominguez MG. Circulating Metabolic Biomarkers of Screen-Detected Prostate Cancer in the ProtecT Study. Cancer Epidemiol Biomarkers Prev. 2019 01; 28(1):208-216. PMID: 30352818; PMCID: PMC6746173.
      Citations: 6     Fields:    Translation:Humans
    27. van der Kwast TH, Helleman J, Nieboer D, Bruinsma SM, Roobol MJ, Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance (GAP3) Consortium, Trock B, Ehdaie B, Carroll P, Filson C, Kim J, Logothetis C, Morgan T, Klotz L, Pickles T, Hyndman E, Moore CM, Gnanapragasam V, Van Hemelrijck M, Dasgupta P, Bangma C, Roobol M, Villers A, Rannikko A, Perry A, Hefermehl L, Shiong LL, Frydenberg M, Kakehi Y, Chung BH, van der Kwast T, Obbink H, van der Linden W, Hulsen T, de Jonge C, Kattan M, Xinge J, Muir K, Lophatananon A, Fahey M, Steyerberg E, Nieboer D, Zhang L, Guo W, Benfante N, Cowan J, Patil D, Tolosa E, Kim TK, Mamedov A, LaPointe V, Crump T, Kimberly-Duffell J, Santaolalla A, Olivier JT, Rancati T, Lehmann K, Lin CH, Hirama H, Lee KS, Jenster G, Auvinen A, Haider M, van Bochove K, Carter B, Gledhill S, Buzza M, Bruinsma S, Helleman J, Valdagni R, Hugosson J, Rubio-Briones J, Bjartell A, Ahlgren H, Mascar?s J, L?fgren A, Bjartell A. Consistent Biopsy Quality and Gleason Grading Within the Global Active Surveillance Global Action Plan 3 Initiative: A Prerequisite for Future Studies. Eur Urol Oncol. 2019 05; 2(3):333-336. PMID: 31200849.
      Citations: 2     Fields:    Translation:Humans
    28. Altok M, Kim B, Patel BB, Shih YT, Ward JF, McRae SE, Chapin BF, Pisters LL, Pettaway CA, Kim J, Demirel HC, Davis JW. Cost and efficacy comparison of five prostate biopsy modalities: a platform for integrating cost into novel-platform comparative research. Prostate Cancer Prostatic Dis. 2018 11; 21(4):524-532. PMID: 29988098.
      Citations: 13     Fields:    Translation:Humans
    29. Schumacher FR, Al Olama AA, Berndt SI, Benlloch S, Ahmed M, Saunders EJ, Dadaev T, Leongamornlert D, Anokian E, Cieza-Borrella C, Goh C, Brook MN, Sheng X, Dennis J, Tyrer J, Muir K, Lophatananon A, Stevens VL, Gapstur SM, Carter BD, Tangen CM, Goodman PJ, Thompson IM, Batra J, Chambers S, Moya L, Clements J, Horvath L, Tilley W, Risbridger GP, Gronberg H, Aly M, Pharoah P, Pashayan N, Schleutker J, Tammela TLJ, Sipeky C, Auvinen A, Albanes D, Weinstein S, Wolk A, West CML, Dunning AM, Burnet N, Mucci LA, Giovannucci E, Andriole GL, Koutros S, Beane Freeman LE, Sorensen KD, Orntoft TF, Borre M, Maehle L, Grindedal EM, Neal DE, Donovan JL, Hamdy FC, Martin RM, Travis RC, Key TJ, Hamilton RJ, Fleshner NE, Finelli A, Ingles SA, Stern MC, Rosenstein BS, Kerns SL, Ostrer H, Lu YJ, Zhang HW, Feng N, Mao X, Guo X, Wang G, Sun Z, Giles GG, Southey MC, MacInnis RJ, FitzGerald LM, Kibel AS, Drake BF, Szulkin R, Eklund M, Kogevinas M, Penney KL, Stampfer M, Park JY, Sellers TA, Lin HY, Stanford JL, Cybulski C, Wokolorczyk D, Lubinski J, Ostrander EA, Geybels MS, Nielsen SF, Weischer M, Bisbjerg R, Iversen P, Brenner H, Cuk K, Maier C, Luedeke M, Schnoeller T, Kim J, Logothetis CJ, John EM, Teixeira MR, Paulo P, Cardoso M, Neuhausen SL, Steele L, Ding YC, De Ruyck K, De Meerleer G, Ost P, Razack A, Lim J, Teo SH, Lin DW, Newcomb LF, Lessel D, Gamulin M, Kulis T, Kaneva R, Usmani N, Singhal S, Slavov C, Mitev V, Parliament M, Claessens F, Joniau S, Van den Broeck T, Larkin S, Townsend PA, Aukim-Hastie C, Martinez ME, Roobol MJ, Jenster G, van Schaik RHN, Menegaux F, Koudou YA, Xu J, Khaw KT, Cannon-Albright L, Pandha H, Michael A, Thibodeau SN, McDonnell SK, Schaid DJ, Lindstrom S, Turman C, Ma J, Hunter DJ, Riboli E, Siddiq A, Canzian F, Kolonel LN, Le Marchand L, Hoover RN, Machiela MJ, Cui Z, Kraft P, Amos CI, Conti DV, Easton DF, Wiklund F, Chanock SJ, Henderson BE, Kote-Jarai Z, Haiman CA, Eeles RA, Profile Study, Australian Prostate Cancer BioResource (APCB), IMPACT Study, Canary PASS Investigators, Breast and Prostate Cancer Cohort Consortium (BPC3), PRACTICAL (Prostate Cancer Association Group to Investigate Cancer-Associated Alterations in the Gen, Cancer of the Prostate in Sweden (CAPS), Prostate Cancer Genome-wide Association Study of Uncommon Susceptibility Loci (PEGASUS), Genetic Associations and Mechanisms in Oncology (GAME-ON)/Elucidating Loci Involved in Prostate Canc, Fachal L, Nordstr?m T, H?kansson N, Cussenot O, Cancel-Tassin G, Vega A, G?mez-Caama?o A, Llorca J, Casta?o-Vinyals G, Nordestgaard BG, R?der MA, Holleczek B, Gago-Dominguez M, Castelao JE, Truong T. Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci. Nat Genet. 2018 07; 50(7):928-936. PMID: 29892016; PMCID: PMC6568012.
      Citations: 253     Fields:    Translation:Humans
    30. Dadaev T, Saunders EJ, Newcombe PJ, Anokian E, Leongamornlert DA, Brook MN, Cieza-Borrella C, Mijuskovic M, Wakerell S, Olama AAA, Schumacher FR, Berndt SI, Benlloch S, Ahmed M, Goh C, Sheng X, Zhang Z, Muir K, Govindasami K, Lophatananon A, Stevens VL, Gapstur SM, Carter BD, Tangen CM, Goodman P, Thompson IM, Batra J, Chambers S, Moya L, Clements J, Horvath L, Tilley W, Risbridger G, Gronberg H, Aly M, Pharoah P, Pashayan N, Schleutker J, Tammela TLJ, Sipeky C, Auvinen A, Albanes D, Weinstein S, Wolk A, Hakansson N, West C, Dunning AM, Burnet N, Mucci L, Giovannucci E, Andriole G, Koutros S, Freeman LEB, Sorensen KD, Orntoft TF, Borre M, Maehle L, Grindedal EM, Neal DE, Donovan JL, Hamdy FC, Martin RM, Travis RC, Key TJ, Hamilton RJ, Fleshner NE, Finelli A, Ingles SA, Stern MC, Rosenstein B, Kerns S, Ostrer H, Lu YJ, Zhang HW, Feng N, Mao X, Guo X, Wang G, Sun Z, Giles GG, Southey MC, MacInnis RJ, FitzGerald LM, Kibel AS, Drake BF, Fachal L, Szulkin R, Eklund M, Kogevinas M, Penney KL, Stampfer M, Park JY, Sellers TA, Lin HY, Stanford JL, Cybulski C, Wokolorczyk D, Lubinski J, Ostrander EA, Geybels MS, Nielsen SF, Weisher M, Bisbjerg R, Iversen P, Brenner H, Cuk K, Maier C, Luedeke M, Schnoeller T, Kim J, Logothetis CJ, John EM, Teixeira MR, Paulo P, Cardoso M, Neuhausen SL, Steele L, Ding YC, De Ruyck K, De Meerleer G, Ost P, Razack A, Lim J, Teo SH, Lin DW, Newcomb LF, Lessel D, Kaneva R, Usmani N, Slavov C, Mitev V, Parliament M, Singhal S, Claessens F, Joniau S, Van den Broeck T, Larkin S, Townsend PA, Aukim-Hastie C, Martinez ME, Roobol MJ, Jenster G, van Schaik RHN, Xu J, Khaw KT, Cannon-Albright L, Pandha H, Michael A, Kierzek A, Thibodeau SN, McDonnell SK, Schaid DJ, Lindstrom S, Turman C, Ma J, Hunter DJ, Riboli E, Siddiq A, Canzian F, Kolonel LN, Le Marchand L, Hoover RN, Machiela MJ, Kraft P, PRACTICAL (Prostate Cancer Association Group to Investigate Cancer-Associated Alterations in the Gen, Freedman M, Wiklund F, Chanock S, Henderson BE, Easton DF, Haiman CA, Eeles RA, Conti DV, Kote-Jarai Z, Nordstr?m T, Cussenot O, Cancel-Tassin G, Vega A, G?mez-Caama?o A, Llorca J, Casta?o-Vinyals G, Nordestgaard BG, R?der MA, Holleczek B, Gamulin M, Kulis T, Gago-Dominguez M, Castelao JE, Menegaux F, Truong T, Koudou YA. Fine-mapping of prostate cancer susceptibility loci in a large meta-analysis identifies candidate causal variants. Nat Commun. 2018 06 11; 9(1):2256. PMID: 29892050; PMCID: PMC5995836.
      Citations: 52     Fields:    Translation:Humans
    31. Kerns SL, Fung C, Monahan PO, Ardeshir-Rouhani-Fard S, Abu Zaid MI, Williams AM, Stump TE, Sesso HD, Feldman DR, Hamilton RJ, Vaughn DJ, Beard C, Huddart RA, Kim J, Kollmannsberger C, Sahasrabudhe DM, Cook R, Fossa SD, Einhorn LH, Travis LB, Platinum Study Group. Cumulative Burden of Morbidity Among Testicular Cancer Survivors After Standard Cisplatin-Based Chemotherapy: A Multi-Institutional Study. J Clin Oncol. 2018 05 20; 36(15):1505-1512. PMID: 29617189; PMCID: PMC5959198.
      Citations: 27     Fields:    Translation:Humans
    32. Zhang W, Liu B, Wu W, Li L, Broom BM, Basourakos SP, Korentzelos D, Luan Y, Wang J, Yang G, Park S, Azad AK, Cao X, Kim J, Corn PG, Logothetis CJ, Aparicio AM, Chinnaiyan AM, Navone N, Troncoso P, Thompson TC. Targeting the MYCN-PARP-DNA Damage Response Pathway in Neuroendocrine Prostate Cancer. Clin Cancer Res. 2018 02 01; 24(3):696-707. PMID: 29138344; PMCID: PMC5823274.
      Citations: 37     Fields:    Translation:HumansAnimalsCells
    33. Blanchard P, Davis JW, Frank SJ, Kim J, Pettaway CA, Pugh TJ, Pisters LL, Ward JF, Choi S, Chapin BF, Hoffman K, Navai N, Achim M, McGuire SE, Matin SF, Nguyen Q, Mahmood U, Graber WJ, Chen HC, Wang X, Kuban DA. Quality of life after brachytherapy or bilateral nerve-sparing robot-assisted radical prostatectomy for prostate cancer: a prospective cohort. BJU Int. 2018 04; 121(4):540-548. PMID: 28941030.
      Citations: 8     Fields:    Translation:Humans
    34. Frank SJ, Pugh TJ, Blanchard P, Mahmood U, Graber WJ, Kudchadker RJ, Davis JW, Kim J, Choi H, Troncoso P, Kuban DA, Choi S, McGuire S, Hoffman KE, Chen HC, Wang X, Swanson DA. Prospective Phase 2 Trial of Permanent Seed Implantation Prostate Brachytherapy for Intermediate-Risk Localized Prostate Cancer: Efficacy, Toxicity, and Quality of Life Outcomes. Int J Radiat Oncol Biol Phys. 2018 02 01; 100(2):374-382. PMID: 29229325.
      Citations: 13     Fields:    Translation:HumansCTClinical Trials
    35. Han Y, Xu J, Kim J, Wu X, Gu J. LINE-1 methylation in peripheral blood leukocytes and clinical characteristics and prognosis of prostate cancer patients. Oncotarget. 2017 Nov 07; 8(55):94020-94027. PMID: 29212206; PMCID: PMC5706852.
      Citations: 4     Fields:    
    36. Basourakos SP, Davis JW, Chapin BF, Ward JF, Pettaway CA, Pisters LL, Navai N, Achim MF, Wang X, Chen HC, Choi S, Kuban D, Troncoso P, Hanash S, Thompson TC, Kim J. Baseline and longitudinal plasma caveolin-1 level as a biomarker in active surveillance for early-stage prostate cancer. BJU Int. 2018 01; 121(1):69-76. PMID: 28710901; PMCID: PMC6126916.
      Citations: 6     Fields:    Translation:Humans
    37. Han Y, Xu J, Kim J, Wu X, Gu J. Methylation of subtelomeric repeat D4Z4 in peripheral blood leukocytes is associated with biochemical recurrence in localized prostate cancer patients. Carcinogenesis. 2017 08 01; 38(8):821-826. PMID: 28854562; PMCID: PMC6248474.
      Citations: 5     Fields:    Translation:HumansCells
    38. Bilen MA, Hess KR, Subudhi SK, Aparicio A, Kim J, Zurita-Saavedra AJ, Araujo JC, Corn PG, Stover J, Lin SH, Logothetis CJ, Tu SM. Clinical predictors of survival in patients with castration-resistant prostate cancer receiving sipuleucel-T cellular immunotherapy. Cancer Chemother Pharmacol. 2017 Sep; 80(3):583-589. PMID: 28730293.
      Citations: 2     Fields:    Translation:Humans
    39. Basourakos SP, Hoffman K, Kim J. Active surveillance in prostate cancer: new efforts, new voices, new hope. BJU Int. 2017 07; 120(1):4-5. PMID: 28621062; PMCID: PMC6051337.
      Citations: 1     Fields:    Translation:HumansPHPublic Health
    40. Dolan ME, El Charif O, Wheeler HE, Gamazon ER, Ardeshir-Rouhani-Fard S, Monahan P, Feldman DR, Hamilton RJ, Vaughn DJ, Beard CJ, Fung C, Kim J, Fossa SD, Hertz DL, Mushiroda T, Kubo M, Einhorn LH, Cox NJ, Travis LB, Platinum Study Group. Clinical and Genome-Wide Analysis of Cisplatin-Induced Peripheral Neuropathy in Survivors of Adult-Onset Cancer. Clin Cancer Res. 2017 Oct 01; 23(19):5757-5768. PMID: 28611204; PMCID: PMC5626588.
      Citations: 31     Fields:    Translation:Humans
    41. Li L, Karanika S, Yang G, Wang J, Park S, Broom BM, Manyam GC, Wu W, Luo Y, Basourakos S, Song JH, Gallick GE, Karantanos T, Korentzelos D, Azad AK, Kim J, Corn PG, Aparicio AM, Logothetis CJ, Troncoso P, Heffernan T, Toniatti C, Lee HS, Lee JS, Zuo X, Chang W, Yin J, Thompson TC. Androgen receptor inhibitor-induced "BRCAness" and PARP inhibition are synthetically lethal for castration-resistant prostate cancer. Sci Signal. 2017 May 23; 10(480). PMID: 28536297; PMCID: PMC5855082.
      Citations: 87     Fields:    Translation:HumansAnimalsCells
    42. Tu H, Gu J, Meng QH, Kim J, Strom S, Davis JW, He Y, Wagar EA, Thompson TC, Logothetis CJ, Wu X. Low serum testosterone is associated with tumor aggressiveness and poor prognosis in prostate cancer. Oncol Lett. 2017 Mar; 13(3):1949-1957. PMID: 28454349; PMCID: PMC5403694.
      Citations: 9     
    43. Basourakos SP, Li L, Aparicio AM, Corn PG, Kim J, Thompson TC. Combination Platinum-based and DNA Damage Response-targeting Cancer Therapy: Evolution and Future Directions. Curr Med Chem. 2017; 24(15):1586-1606. PMID: 27978798; PMCID: PMC5471128.
      Citations: 32     Fields:    Translation:HumansCells
    44. Wheeler HE, Gamazon ER, Frisina RD, Perez-Cervantes C, El Charif O, Mapes B, Fossa SD, Feldman DR, Hamilton RJ, Vaughn DJ, Beard CJ, Fung C, Kollmannsberger C, Kim J, Mushiroda T, Kubo M, Ardeshir-Rouhani-Fard S, Einhorn LH, Cox NJ, Dolan ME, Travis LB. Variants in WFS1 and Other Mendelian Deafness Genes Are Associated with Cisplatin-Associated Ototoxicity. Clin Cancer Res. 2017 07 01; 23(13):3325-3333. PMID: 28039263; PMCID: PMC5493516.
      Citations: 31     Fields:    Translation:Humans
    45. Bilen MA, Cauley DH, Atkinson BJ, Chen HC, Kaya DH, Wang X, Vikram R, Tu SM, Corn PG, Kim J. Safety of Same-day Pegfilgrastim Administration in Metastatic Castration-resistant Prostate Cancer Treated With Cabazitaxel With or Without Carboplatin. Clin Genitourin Cancer. 2017 06; 15(3):e429-e435. PMID: 28038931; PMCID: PMC5446270.
      Citations: 4     Fields:    Translation:Humans
    46. Shu X, Ye Y, Gu J, He Y, Davis JW, Thompson TC, Logothetis CJ, Kim J, Wu X. Genetic variants of the Wnt signaling pathway as predictors of aggressive disease and reclassification in men with early stage prostate cancer on active surveillance. Carcinogenesis. 2016 Oct; 37(10):965-971. PMID: 27515962; PMCID: PMC5035398.
      Citations: 4     Fields:    Translation:HumansCellsCTClinical Trials
    47. Karantanos T, Karanika S, Wang J, Yang G, Dobashi M, Park S, Ren C, Li L, Basourakos SP, Hoang A, Efstathiou E, Wang X, Troncoso P, Titus M, Broom B, Kim J, Corn PG, Logothetis CJ, Thompson TC. Caveolin-1 regulates hormone resistance through lipid synthesis, creating novel therapeutic opportunities for castration-resistant prostate cancer. Oncotarget. 2016 Jul 19; 7(29):46321-46334. PMID: 27331874; PMCID: PMC5216801.
      Citations: 9     Fields:    Translation:HumansAnimals
    48. Kim J, Davis JW, Klein EA, Magi-Galluzzi C, Lotan Y, Ward JF, Pisters LL, Basler JW, Pettaway CA, Stephenson A, Li Ning Tapia EM, Efstathiou E, Wang X, Do KA, Lee JJ, Gorlov IP, Vornik LA, Hoque AM, Prokhorova IN, Parnes HL, Lippman SM, Thompson IM, Brown PH, Logothetis CJ, Troncoso P. Tissue Effects in a Randomized Controlled Trial of Short-term Finasteride in Early Prostate Cancer. EBioMedicine. 2016 May; 7:85-93. PMID: 27322462; PMCID: PMC4909608.
      Citations: 2     Fields:    Translation:Humans
    49. Kalra S, Basourakos S, Abouassi A, Achim M, Volk RJ, Hoffman KE, Davis JW, Kim J. The implications of ageing and life expectancy in prostate cancer treatment. Nat Rev Urol. 2016 May; 13(5):289-95. PMID: 27001016.
      Citations: 4     Fields:    Translation:Humans
    50. Tu H, Gu J, Meng QH, Kim J, Davis JW, He Y, Wagar EA, Thompson TC, Logothetis CJ, Wu X. Mitochondrial DNA copy number in peripheral blood leukocytes and the aggressiveness of localized prostate cancer. Oncotarget. 2015 Dec 08; 6(39):41988-96. PMID: 26515605; PMCID: PMC4747203.
      Citations: 12     Fields:    Translation:HumansCells
    51. Davis JW, Ward JF, Pettaway CA, Wang X, Kuban D, Frank SJ, Lee AK, Pisters LL, Matin SF, Shah JB, Karam JA, Chapin BF, Papadopoulos JN, Achim M, Hoffman KE, Pugh TJ, Choi S, Troncoso P, Logothetis CJ, Kim J. Disease reclassification risk with stringent criteria and frequent monitoring in men with favourable-risk prostate cancer undergoing active surveillance. BJU Int. 2016 07; 118(1):68-76. PMID: 26059275; PMCID: PMC4808616.
      Citations: 17     Fields:    Translation:Humans
    52. Parker PA, Davis JW, Latini DM, Baum G, Wang X, Ward JF, Kuban D, Frank SJ, Lee AK, Logothetis CJ, Kim J. Relationship between illness uncertainty, anxiety, fear of progression and quality of life in men with favourable-risk prostate cancer undergoing active surveillance. BJU Int. 2016 Mar; 117(3):469-77. PMID: 25714186; PMCID: PMC4547910.
      Citations: 39     Fields:    Translation:Humans
    53. Mintz PJ, Rietz AC, Ozawa MG, Dondossola E, Do KA, Kim J, Troncoso P, Logothetis CJ, Sidman RL, Pasqualini R, Arap W, Card?-Vila M. Discovery and horizontal follow-up of an autoantibody signature in human prostate cancer. Proc Natl Acad Sci U S A. 2015 Feb 24; 112(8):2515-20. PMID: 25675522; PMCID: PMC4345585.
      Citations: 25     Fields:    Translation:HumansCells
    54. He Y, Gu J, Strom S, Logothetis CJ, Kim J, Wu X. The prostate cancer susceptibility variant rs2735839 near KLK3 gene is associated with aggressive prostate cancer and can stratify gleason score 7 patients. Clin Cancer Res. 2014 Oct 01; 20(19):5133-5139. PMID: 25274378; PMCID: PMC4185411.
      Citations: 19     Fields:    Translation:Humans
    55. Hoffman KE, Niu J, Shen Y, Jiang J, Davis JW, Kim J, Kuban DA, Perkins GH, Shah JB, Smith GL, Volk RJ, Buchholz TA, Giordano SH, Smith BD. Physician variation in management of low-risk prostate cancer: a population-based cohort study. JAMA Intern Med. 2014 Sep; 174(9):1450-9. PMID: 25023650; PMCID: PMC4372187.
      Citations: 48     Fields:    Translation:Humans
    56. Madsen LT, Kuban DA, Choi S, Davis JW, Kim J, Lee AK, Domain D, Levy L, Pisters LL, Pettaway CA, Ward JF, Logothetis C, Hoffman KE. Impact of a clinical trial initiative on clinical trial enrollment in a multidisciplinary prostate cancer clinic. J Natl Compr Canc Netw. 2014 Jul; 12(7):993-8. PMID: 24994920; PMCID: PMC4413899.
      Citations: 3     Fields:    Translation:Humans
    57. Logothetis CJ, Gallick GE, Maity SN, Kim J, Aparicio A, Efstathiou E, Lin SH. Molecular classification of prostate cancer progression: foundation for marker-driven treatment of prostate cancer. Cancer Discov. 2013 Aug; 3(8):849-61. PMID: 23811619; PMCID: PMC3926428.
      Citations: 66     Fields:    Translation:Humans
    58. Aparicio AM, Harzstark AL, Corn PG, Wen S, Araujo JC, Tu SM, Pagliaro LC, Kim J, Millikan RE, Ryan C, Tannir NM, Zurita AJ, Mathew P, Arap W, Troncoso P, Thall PF, Logothetis CJ. Platinum-based chemotherapy for variant castrate-resistant prostate cancer. Clin Cancer Res. 2013 Jul 01; 19(13):3621-30. PMID: 23649003; PMCID: PMC3699964.
      Citations: 136     Fields:    Translation:Humans
    59. Kim J, Ebertowski J, Janiga M, Arzola J, Gillespie G, Fountain M, Soderdahl D, Canby-Hagino E, Elsamanoudi S, Gurski J, Davis JW, Parker PA, Boyd DD. Many young men with prostate-specific antigen (PSA) screen-detected prostate cancers may be candidates for active surveillance. BJU Int. 2013 May; 111(6):934-40. PMID: 23350937; PMCID: PMC3637421.
      Citations: 3     Fields:    Translation:HumansPHPublic Health
    60. Bilen MA, Kim J, Wang H, Tu SM. Cixutumumab-associated pancolitis in a patient with prostate cancer. Clin Genitourin Cancer. 2013 Jun; 11(2):207-10. PMID: 23083799; PMCID: PMC3579009.
      Citations:    Fields:    Translation:Humans
    61. Yang P, Cartwright CA, Li J, Wen S, Prokhorova IN, Shureiqi I, Troncoso P, Navone NM, Newman RA, Kim J. Arachidonic acid metabolism in human prostate cancer. Int J Oncol. 2012 Oct; 41(4):1495-503. PMID: 22895552; PMCID: PMC3982713.
      Citations: 24     Fields:    Translation:HumansCells
    62. Kim J, Davis JW. Prostate cancer screening--time to abandon one-size-fits-all approach? JAMA. 2011 Dec 28; 306(24):2717-8. PMID: 22203541.
      Citations: 6     Fields:    Translation:HumansPHPublic Health
    63. Kim J, Amos CI, Logothetis C. 5a-Reductase inhibitors for prostate-cancer prevention. N Engl J Med. 2011 Dec 15; 365(24):2340. PMID: 22168662.
      Citations: 2     Fields:    Translation:Humans
    64. Li J, Ding Z, Wang Z, Lu JF, Maity SN, Navone NM, Logothetis CJ, Mills GB, Kim J. Androgen regulation of 5a-reductase isoenzymes in prostate cancer: implications for prostate cancer prevention. PLoS One. 2011; 6(12):e28840. PMID: 22194926; PMCID: PMC3237548.
      Citations: 22     Fields:    Translation:HumansAnimalsCells
    65. del Junco DJ, Fox EE, Cooper S, Goldhagen M, Koda E, Rogers D, Canby-Hagino E, Kim J, Pettaway C, Boyd DD. Increasing low risk prostate cancer incidence in United States Air Force servicemen and selection of treatments. J Urol. 2011 Jun; 185(6):2137-42. PMID: 21496842; PMCID: PMC3171171.
      Citations:    Fields:    Translation:Humans
    66. Kim J. Chemoprevention of prostate cancer: breakthroughs and controversies. Expert Rev Anticancer Ther. 2010 Oct; 10(10):1517-22. PMID: 20942621.
      Citations: 1     Fields:    Translation:HumansPHPublic Health
    67. Davis JW, Kim J, Ward JF, Wang X, Nakanishi H, Babaian RJ, Troncoso P. Radical prostatectomy findings in patients predicted to have low-volume/low-grade prostate cancer diagnosed by extended-core biopsies: an analysis of volume and zonal distribution of tumour foci. BJU Int. 2010 May; 105(10):1386-91. PMID: 19888979; PMCID: PMC6204225.
      Citations: 12     Fields:    Translation:Humans
    68. Efstathiou E, Kim J, Logothetis CJ. Informative clinical investigation: a demanding taskmaster. J Clin Oncol. 2009 Oct 20; 27(30):4937-8. PMID: 19720892.
      Citations: 1     Fields:    Translation:Humans
    69. Li J, Kim J. Molecular profiles of finasteride effects on prostate carcinogenesis. Cancer Prev Res (Phila). 2009 Jun; 2(6):518-24. PMID: 19491289.
      Citations: 3     Fields:    Translation:HumansAnimalsCells
    70. Blando J, Portis M, Benavides F, Alexander A, Mills G, Dave B, Conti CJ, Kim J, Walker CL. PTEN deficiency is fully penetrant for prostate adenocarcinoma in C57BL/6 mice via mTOR-dependent growth. Am J Pathol. 2009 May; 174(5):1869-79. PMID: 19395652; PMCID: PMC2671275.
      Citations: 20     Fields:    Translation:HumansAnimalsCells
    71. Tsavachidou D, McDonnell TJ, Wen S, Wang X, Vakar-Lopez F, Pisters LL, Pettaway CA, Wood CG, Do KA, Thall PF, Stephens C, Efstathiou E, Taylor R, Menter DG, Troncoso P, Lippman SM, Logothetis CJ, Kim J. Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer. J Natl Cancer Inst. 2009 Mar 04; 101(5):306-20. PMID: 19244175; PMCID: PMC2734116.
      Citations: 26     Fields:    Translation:HumansCTClinical Trials
    72. Lin SH, Lee YC, Choueiri MB, Wen S, Mathew P, Ye X, Do KA, Navone NM, Kim J, Tu SM, Yu-Lee LY, Logothetis CJ. Soluble ErbB3 levels in bone marrow and plasma of men with prostate cancer. Clin Cancer Res. 2008 Jun 15; 14(12):3729-36. PMID: 18559590; PMCID: PMC2562877.
      Citations: 9     Fields:    Translation:Humans
    73. Lin SH, Cheng CJ, Lee YC, Ye X, Tsai WW, Kim J, Pasqualini R, Arap W, Navone NM, Tu SM, Hu M, Yu-Lee LY, Logothetis CJ. A 45-kDa ErbB3 secreted by prostate cancer cells promotes bone formation. Oncogene. 2008 Sep 04; 27(39):5195-203. PMID: 18490922; PMCID: PMC2562662.
      Citations: 17     Fields:    Translation:HumansAnimalsCells
    74. Jonasch E, Wood C, Tamboli P, Pagliaro LC, Tu SM, Kim J, Srivastava P, Perez C, Isakov L, Tannir N. Vaccination of metastatic renal cell carcinoma patients with autologous tumour-derived vitespen vaccine: clinical findings. Br J Cancer. 2008 Apr 22; 98(8):1336-41. PMID: 18362942; PMCID: PMC2361701.
      Citations: 20     Fields:    Translation:HumansPHPublic Health
    75. Mao S, Daliani DD, Wang X, Thall PF, Do KA, Perez CA, Brown MA, Bouchillon K, Carter CM, Logothetis CJ, Kim J. Employing the treatment-free interval of intermittent androgen ablation to screen candidate prostate cancer therapies. Prostate. 2007 Nov 01; 67(15):1677-85. PMID: 17879948.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    76. Cheng CJ, Ye XC, Vakar-Lopez F, Kim J, Tu SM, Chen DT, Navone NM, Yu-Lee LY, Lin SH, Hu MC. Bone microenvironment and androgen status modulate subcellular localization of ErbB3 in prostate cancer cells. Mol Cancer Res. 2007 Jul; 5(7):675-84. PMID: 17634423; PMCID: PMC2000833.
      Citations: 19     Fields:    Translation:HumansCells
    77. Kelloff GJ, Lippman SM, Dannenberg AJ, Sigman CC, Pearce HL, Reid BJ, Szabo E, Jordan VC, Spitz MR, Mills GB, Papadimitrakopoulou VA, Lotan R, Aggarwal BB, Bresalier RS, Kim J, Arun B, Lu KH, Thomas ME, Rhodes HE, Brewer MA, Follen M, Shin DM, Parnes HL, Siegfried JM, Evans AA, Blot WJ, Chow WH, Blount PL, Maley CC, Wang KK, Lam S, Lee JJ, Dubinett SM, Engstrom PF, Meyskens FL, O'Shaughnessy J, Hawk ET, Levin B, Nelson WG, Hong WK, AACR Task Force on Cancer Prevention. Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer--a plan to move forward. Clin Cancer Res. 2006 Jun 15; 12(12):3661-97. PMID: 16778094.
      Citations: 88     Fields:    Translation:HumansCells
    78. Subbarayan V, Krieg P, Hsi LC, Kim J, Yang P, Sabichi AL, Llansa N, Mendoza G, Logothetis CJ, Newman RA, Lippman SM, Menter DG. 15-Lipoxygenase-2 gene regulation by its product 15-(S)-hydroxyeicosatetraenoic acid through a negative feedback mechanism that involves peroxisome proliferator-activated receptor gamma. Oncogene. 2006 Sep 28; 25(44):6015-25. PMID: 16682954.
      Citations: 9     Fields:    Translation:HumansCells
    79. Tu SM, Kim J, Pagliaro LC, Vakar-Lopez F, Wong FC, Wen S, General R, Podoloff DA, Lin SH, Logothetis CJ. Therapy tolerance in selected patients with androgen-independent prostate cancer following strontium-89 combined with chemotherapy. J Clin Oncol. 2005 Nov 01; 23(31):7904-10. PMID: 16258090.
      Citations: 16     Fields:    Translation:Humans
    80. Lee SH, Nishino M, Mazumdar T, Garcia GE, Galfione M, Lee FL, Lee CL, Liang A, Kim J, Feng L, Eissa NT, Lin SH, Yu-Lee LY. 16-kDa prolactin down-regulates inducible nitric oxide synthase expression through inhibition of the signal transducer and activator of transcription 1/IFN regulatory factor-1 pathway. Cancer Res. 2005 Sep 01; 65(17):7984-92. PMID: 16140971.
      Citations: 10     Fields:    Translation:AnimalsCells
    81. Kim J, Yang P, Suraokar M, Sabichi AL, Llansa ND, Mendoza G, Subbarayan V, Logothetis CJ, Newman RA, Lippman SM, Menter DG. Suppression of prostate tumor cell growth by stromal cell prostaglandin D synthase-derived products. Cancer Res. 2005 Jul 15; 65(14):6189-98. PMID: 16024620.
      Citations: 27     Fields:    Translation:HumansCells
    82. Kim J, Sun P, Lam YW, Troncoso P, Sabichi AL, Babaian RJ, Pisters LL, Pettaway CA, Wood CG, Lippman SM, McDonnell TJ, Lieberman R, Logothetis C, Ho SM. Changes in serum proteomic patterns by presurgical alpha-tocopherol and L-selenomethionine supplementation in prostate cancer. Cancer Epidemiol Biomarkers Prev. 2005 Jul; 14(7):1697-702. PMID: 16030104.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    83. Subbarayan V, Xu XC, Kim J, Yang P, Hoque A, Sabichi AL, Llansa N, Mendoza G, Logothetis CJ, Newman RA, Lippman SM, Menter DG. Inverse relationship between 15-lipoxygenase-2 and PPAR-gamma gene expression in normal epithelia compared with tumor epithelia. Neoplasia. 2005 Mar; 7(3):280-93. PMID: 15799828; PMCID: PMC1501140.
      Citations: 20     Fields:    Translation:HumansCells
    84. Subbarayan V, Sabichi AL, Kim J, Llansa N, Logothetis CJ, Lippman SM, Menter DG. Differential peroxisome proliferator-activated receptor-gamma isoform expression and agonist effects in normal and malignant prostate cells. Cancer Epidemiol Biomarkers Prev. 2004 Nov; 13(11 Pt 1):1710-6. PMID: 15533897.
      Citations: 15     Fields:    Translation:HumansAnimalsCells
    85. Fizazi K, Sikes CR, Kim J, Yang J, Martinez LA, Olive MC, Logothetis CJ, Navone NM. High efficacy of docetaxel with and without androgen deprivation and estramustine in preclinical models of advanced prostate cancer. Anticancer Res. 2004 Sep-Oct; 24(5A):2897-903. PMID: 15517894.
      Citations: 10     Fields:    Translation:HumansAnimalsCells
    86. Papandreou CN, Daliani DD, Nix D, Yang H, Madden T, Wang X, Pien CS, Millikan RE, Tu SM, Pagliaro L, Kim J, Adams J, Elliott P, Esseltine D, Petrusich A, Dieringer P, Perez C, Logothetis CJ. Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer. J Clin Oncol. 2004 Jun 01; 22(11):2108-21. PMID: 15169797.
      Citations: 151     Fields:    Translation:HumansCTClinical Trials
    87. Vakar-Lopez F, Cheng CJ, Kim J, Shi GG, Troncoso P, Tu SM, Yu-Lee LY, Lin SH. Up-regulation of MDA-BF-1, a secreted isoform of ErbB3, in metastatic prostate cancer cells and activated osteoblasts in bone marrow. J Pathol. 2004 Jun; 203(2):688-95. PMID: 15141384.
      Citations: 16     Fields:    Translation:HumansCells
    88. Salas TR, Kim J, Vakar-Lopez F, Sabichi AL, Troncoso P, Jenster G, Kikuchi A, Chen SY, Shemshedini L, Suraokar M, Logothetis CJ, DiGiovanni J, Lippman SM, Menter DG. Glycogen synthase kinase-3 beta is involved in the phosphorylation and suppression of androgen receptor activity. J Biol Chem. 2004 Apr 30; 279(18):19191-200. PMID: 14985354.
      Citations: 37     Fields:    Translation:HumansCells
    89. Tu SM, Millikan RE, Pagliaro LC, Daliani D, Papandreou CN, Kim J, Chen DT, Williams DL, Logothetis CJ. Treatment of refractory urothelial carcinoma with alternating paclitaxel, methotrexate, cisplatin (TMP) and 5-fluorouracil, alpha-interferon, cisplatin (FAP). Urol Oncol. 2003 Sep-Oct; 21(5):342-8. PMID: 14670540.
      Citations:    Fields:    Translation:Humans
    90. Galfione M, Luo W, Kim J, Hawke D, Kobayashi R, Clapp C, Yu-Lee LY, Lin SH. Expression and purification of the angiogenesis inhibitor 16-kDa prolactin fragment from insect cells. Protein Expr Purif. 2003 Apr; 28(2):252-8. PMID: 12699689.
      Citations: 14     Fields:    Translation:HumansAnimalsCells
    91. Kim J, Luo W, Chen DT, Earley K, Tunstead J, Yu-Lee LY, Lin SH. Antitumor activity of the 16-kDa prolactin fragment in prostate cancer. Cancer Res. 2003 Jan 15; 63(2):386-93. PMID: 12543792.
      Citations: 13     Fields:    Translation:HumansAnimalsCells
    92. Kim J, Millikan RE, Smith TL, Tu SM, Pagliaro LC, Logothetis CJ. Treating refractory advanced or metastatic urothelial carcinoma with interleukin-2: a phase II study. Urol Oncol. 2003 Jan-Feb; 21(1):21-6. PMID: 12684123.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    93. Mintz PJ, Kim J, Do KA, Wang X, Zinner RG, Cristofanilli M, Arap MA, Hong WK, Troncoso P, Logothetis CJ, Pasqualini R, Arap W. Fingerprinting the circulating repertoire of antibodies from cancer patients. Nat Biotechnol. 2003 Jan; 21(1):57-63. PMID: 12496764.
      Citations: 104     Fields:    Translation:HumansCells
    94. Zinner RG, Kim J, Herbst RS. Non-small cell lung cancer clinical trials with trastuzumab: their foundation and preliminary results. Lung Cancer. 2002 Jul; 37(1):17-27. PMID: 12057863.
      Citations: 6     Fields:    Translation:Humans
    95. Fizazi K, Prow DM, Do KA, Wang X, Finn L, Kim J, Daliani D, Papandreou CN, Tu SM, Millikan RE, Pagliaro LC, Logothetis CJ, Amato RJ. Alternating dose-dense chemotherapy in patients with high volume disseminated non-seminomatous germ cell tumours. Br J Cancer. 2002 May 20; 86(10):1555-60. PMID: 12085204; PMCID: PMC2746595.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    96. Tu SM, Millikan RE, Mengistu B, Delpassand ES, Amato RJ, Pagliaro LC, Daliani D, Papandreou CN, Smith TL, Kim J, Podoloff DA, Logothetis CJ. Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial. Lancet. 2001 Feb 03; 357(9253):336-41. PMID: 11210994.
      Citations: 88     Fields:    Translation:HumansCTClinical Trials
    97. Newman RA, Kim J, Newman BM, Bruno R, Bayssas M, Klink-Alaki M, Pazdur R. Phase I trial of intoplicine (RP 60475) administered as a 72 h infusion every 3 weeks in patients with solid tumors. Anticancer Drugs. 1999 Nov; 10(10):889-94. PMID: 10630356.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    98. Kim J, Logothetis CJ. Serologic tumor markers, clinical biology, and therapy of prostatic carcinoma. Urol Clin North Am. 1999 May; 26(2):281-90. PMID: 10361551.
      Citations: 2     Fields:    Translation:Humans
    99. Kim J, Zhi J, Satoh H, Koss-Twardy SG, Passe SM, Patel IH, Pazdur R. Pharmacokinetics of recombinant human interferon-alpha 2a combined with 5-fluorouracil in patients with advanced colorectal carcinoma. Anticancer Drugs. 1998 Sep; 9(8):689-96. PMID: 9823427.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    100. Hjelle B, Goade D, Torrez-Martinez N, Lang-Williams M, Kim J, Harris RL, Rawlings JA. Hantavirus pulmonary syndrome, renal insufficiency, and myositis associated with infection by Bayou hantavirus. Clin Infect Dis. 1996 Sep; 23(3):495-500. PMID: 8879771.
      Citations: 15     Fields:    Translation:HumansCells
    101. Recommendations on use of prostate-specific antigen for prostate cancer screening - Reply [3]. JAMA - Journal of the American Medical Association. 307:1373.
    102. Genetic variants of the Wnt signaling pathway as predictors of aggressive disease and reclassification in men with early stage prostate cancer on active surveillance. Carcinogenesis. 37:965-971.
    103. Predicting high-throughput screening results with scalable literature-based discovery methods. CPT: Pharmacometrics and Systems Pharmacology. 3.
    104. Genitourinary cancer survivorship management. 95-124.
    105. Caveolin-1 regulates hormone resistance through lipid synthesis, creating novel therapeutic opportunities for castration-resistant prostate cancer. Oncotarget. 7:46321-46334.
    106. The pattern of serum markers in patients with androgen-independent adenocarcinoma of the prostate. Urologic Oncology. 5:97-103.
    107. Tissue Effects in a Randomized Controlled Trial of Short-term Finasteride in Early Prostate Cancer. EBioMedicine.
    108. The implications of ageing and life expectancy in prostate cancer treatment. Nature Reviews Urology. 13:289-295.
    109. Mitochondrial DNA copy number in peripheral blood leukocytes and the aggressiveness of localized prostate cancer. Oncotarget. 6:41988-41996.
    110. Safety of Same-day Pegfilgrastim Administration in Metastatic Castration-resistant Prostate Cancer Treated With Cabazitaxel With or Without Carboplatin. Clinical Genitourinary Cancer.
    111. Relationship between illness uncertainty, anxiety, fear of progression and quality of life in men with favourable-risk prostate cancer undergoing active surveillance. BJU International. 117:469-477.
    KIM's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (496)
    Explore
    _
    Co-Authors (86)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _